A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors

A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-typeKRASwho have received first-line systemic therapy

(2016) Cathy Eng et al.   INTERNATIONAL JOURNAL OF CANCER

A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study)

(2015) H. Yoshioka et al.   ANNALS OF ONCOLOGY

Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer

(2015) Sara M. Tolaney et al.   INVESTIGATIONAL NEW DRUGS

Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tivantinib (ARQ 197) Plus Erlotinib Versus Erlotinib Alone in Previously Treated Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2015) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors

(2014) S. Pant et al.   ANNALS OF ONCOLOGY

Phase 1 trial of tivantinib in combination with sorafenib in adult patients with advanced solid tumors

(2014) Igor Puzanov et al.   INVESTIGATIONAL NEW DRUGS

CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer

(2013) N Yamamoto et al.   BRITISH JOURNAL OF CANCER

Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition

(2013) R. Katayama et al.   CANCER RESEARCH

Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET

(2013) C. Basilico et al.   CLINICAL CANCER RESEARCH

Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib

(2012) Jonathan W. Goldman et al.   CANCER

Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors

(2012) Andrew J. Wagner et al.   CANCER

Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study

(2012) Armando Santoro et al.   LANCET ONCOLOGY

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

(2011) L. S. Rosen et al.   CLINICAL CANCER RESEARCH

Phase I Trial of a Selective c-MET Inhibitor ARQ 197 Incorporating Proof of Mechanism Pharmacodynamic Studies

(2011) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

(2011) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity

(2010) N. Munshi et al.   MOLECULAR CANCER THERAPEUTICS

Intravenous Temsirolimus in Cancer Patients: Clinical Pharmacology and Dosing Considerations

(2009) Joseph P. Boni et al.   SEMINARS IN ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER